---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-113526"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2024-10-08T23:59:59+00:00"
generated_at: "2026-05-30T17:54:26.012333+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TuHURA reports H1 2024 net loss $10.1M, cash $12.3M; merger with Kintara on track for Q4 2024

## Summary
- Net loss $10.1M for six months ended June 30, 2024; prior period loss $22.1M incl $16.2M IPR&D charge.
- Cash $12.3M as of June 30, 2024, up from $3.7M at Dec 31, 2023; R&D expense $6.4M vs $4.0M YoY.
- Convertible notes payable net $16.2M; derivative liability $2.0M; accumulated deficit $98.6M.
- All-stock merger with Kintara expected to close Q4 2024; combined company to trade as HURA.

## SEC filing metadata
- accession: 0000950170-24-113526
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2024-10-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017024113526/0000950170-24-113526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017024113526/ktra-20241007.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-113526
- JSON: https://secwatch.observer/filing/0000950170-24-113526.json
- Plain text: https://secwatch.observer/filing/0000950170-24-113526.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.